Literature DB >> 19152401

Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy.

Alberto Agarossi1, Enrico Ferrazzi, Fabio Parazzini, Carlo Federico Perno, Luciano Ghisoni.   

Abstract

The aim of this survey was to assess the prevalence and distribution of oncogenic human papillomavirus (HPV) genotypes in women who underwent screening for cervical cancer in Italy. The correlation of genotypes with the cytological results was also evaluated. Cervical samples were collected from 9,947 self-referring women for cervical cancer screening. Participants were screened by liquid-based cytology and high-risk HPV testing using the Hybrid Capture 2 test. Positive samples were genotyped by PCR. Samples (1,474; 14.8%) were positive for high-risk HPV. The prevalence was 29.4% in the 15-19 years-group, decreasing progressively to 6.1% at 50-54 years of age and increasing to 12.2% in those aged over 65 years. HPV 16 was the genotype detected most frequently followed by HPV 31, HPV 18, HPV 56, and HPV 51. HPV 16 or 18 were present in 4% of women with normal cytology and both were detected contemporarily in only 14 women. Twenty-two percent of atypical squamous cells, 26% of low-grade and 56% of high-grade squamous intraepithelial lesions at cytology were positive for HPV 16 and/or 18. The prevalence of HPV infection in Italy is in agreement with that reported worldwide. HPV 16 was the prevalent genotype. The concomitant infection with HPV 16 and HPV 18 (vaccine targets) was found rarely. Apart from HPV 16 and 18, there was a substantial presence of HPV genotypes against which the vaccines available currently have shown cross-protection efficacy. The findings of this study may contribute to reliable predictions on the potential efficacy of an HPV vaccine in clinical practice. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19152401     DOI: 10.1002/jmv.21347

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  19 in total

1.  High risk HPV DNA subtypes and E6/E7 mRNA expression in a cohort of colposcopy patients from Northern Italy with high-grade histologically verified cervical lesions.

Authors:  Liverani Ca; Ciavattini A; Monti E; Puglia D; Mangano S; D I Giuseppe J; Zizzi A; Goteri G; Bolis G
Journal:  Am J Transl Res       Date:  2012-10-10       Impact factor: 4.060

2.  Lactobacillus crispatus M247 oral administration: Is it really an effective strategy in the management of papillomavirus-infected women?

Authors:  Miriam Dellino; Eliano Cascardi; Antonio Simone Laganà; Giovanni Di Vagno; Antonio Malvasi; Rosanna Zaccaro; Katia Maggipinto; Gerardo Cazzato; Salvatore Scacco; Raffaele Tinelli; Alessandro De Luca; Marina Vinciguerra; Vera Loizzi; Antonella Daniele; Ettore Cicinelli; Carmine Carriero; Chiara Antonia Genco; Gennaro Cormio; Vincenzo Pinto
Journal:  Infect Agent Cancer       Date:  2022-10-21       Impact factor: 3.698

3.  Human papillomavirus types distribution in eastern Sicilian females with cervical lesions. A correlation with colposcopic and histological findings.

Authors:  Maria Le Donne; Giuseppe Giuffrè; Carmela Caruso; Piero Antonio Nicotina; Angela Alibrandi; Rosalba Scalisi; Angela Simone; Benito Chiofalo; Onofrio Triolo
Journal:  Pathol Oncol Res       Date:  2013-02-19       Impact factor: 3.201

4.  Human papillomavirus type distribution and correlation with cyto-histological patterns in women from the South of Italy.

Authors:  Paola Menegazzi; Luisa Barzon; Giorgio Palù; Elisa Reho; Luigi Tagliaferro
Journal:  Infect Dis Obstet Gynecol       Date:  2010-01-24

5.  Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study.

Authors:  Paolo Giorgi Rossi; Simonetta Bisanzi; Irene Paganini; Angela Di Iasi; Claudio Angeloni; Aurora Scalisi; Rosalba Macis; Maria Teresa Pini; Francesco Chini; Francesca Maria Carozzi
Journal:  BMC Infect Dis       Date:  2010-07-20       Impact factor: 3.090

6.  Distribution of high-risk human papillomavirus genotypes among HIV-negative women with and without cervical intraepithelial neoplasia in South Africa.

Authors:  Alicia C McDonald; Lynette Denny; Chunhui Wang; Wei-Yann Tsai; Thomas C Wright; Louise Kuhn
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

7.  A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18-26 years.

Authors:  Cristina Giambi; Serena Donati; Francesca Carozzi; Stefania Salmaso; Silvia Declich; Marta L Ciofi degli Atti; Guglielmo Ronco; Maria P Alibrandi; Silvia Brezzi; Natalina Collina; Daniela Franchi; Amedeo Lattanzi; Maria C Minna; Roberto Nannini; Elena Barretta; Elena Burroni; Anna Gillio-Tos; Vincenzo Macallini; Paola Pierotti; Antonino Bella
Journal:  BMC Infect Dis       Date:  2013-02-07       Impact factor: 3.090

8.  Prevalence and type distribution of human papillomavirus infection in women from North Sardinia, Italy.

Authors:  Andrea Piana; Giovanni Sotgiu; Paolo Castiglia; Stefania Pischedda; Clementina Cocuzza; Giampiero Capobianco; Vincenzo Marras; Salvatore Dessole; Elena Muresu
Journal:  BMC Public Health       Date:  2011-10-11       Impact factor: 3.295

9.  Oncogenic human papillomavirus genital infection in southern Iranian women: population-based study versus clinic-based data.

Authors:  Seyed Sajjad Eghbali; Roya Amirinejad; Narges Obeidi; Shiva Mosadeghzadeh; Katayoun Vahdat; Fatemeh Azizi; Raha Pazoki; Zahra Sanjdideh; Zahra Amiri; Iraj Nabipour; Keivan Zandi
Journal:  Virol J       Date:  2012-09-12       Impact factor: 4.099

10.  High HPV-51 prevalence in invasive cervical cancers: results of a pre-immunization survey in North Sardinia, Italy.

Authors:  Andrea Piana; Giovanni Sotgiu; Clementina Cocuzza; Rosario Musumeci; Vincenzo Marras; Stefania Pischedda; Silvia Deidda; Elena Muresu; Paolo Castiglia
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.